Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase

Andrew Maynard; Renae M Crosby; Byron Ellis; Robert Hamatake; Zhi Hong; Brian A Johns; Kirsten M Kahler; Cecilia Koble; Anna L Leivers; Martin R Leivers; Amanda Mathis; Andrew J Peat; Jeffrey J Pouliot; Christopher D Roberts; Vicente Samano; Rachel M Schmidt; Gary K Smith; Andrew Spaltenstein; Eugene L Stewart; Pia Thommes; Elizabeth M Turner; Christian Voitenleitner; Jill T Walker; Greg Waitt; Jason Weatherhead; Kurt L Weaver; Shawn Williams; Lois Wright; Zhiping Z Xiong; David Haigh; J Brad Shotwell

doi:10.1021/jm400317w

Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase

Andrew Maynard, Renae M Crosby, Byron Ellis, Robert Hamatake, Zhi Hong, Brian A Johns, Kirsten M Kahler, Cecilia Koble, Anna L Leivers, Martin R Leivers, Amanda Mathis, Andrew J Peat, Jeffrey J Pouliot, Christopher D Roberts, Vicente Samano, Rachel M Schmidt, Gary K Smith, Andrew Spaltenstein, Eugene L Stewart, Pia ThommesElizabeth M Turner, Christian Voitenleitner, Jill T Walker, Greg Waitt, Jason Weatherhead, Kurt L Weaver, Shawn Williams, Lois Wright, Zhiping Z Xiong, David Haigh, J Brad Shotwell

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)

Abstract

A boronic acid moiety was found to be a critical pharmacophore for enhanced in vitro potency against wild type hepatitis C replicons and known clinical polymorphic and resistant HCV mutant replicons. The synthesis, optimization, and structure-activity relationships associated with inhibition of HCV replication in a sub-genomic replication system for a series of non-nucleoside boron-containing HCV RNA-Dependent RNA Polymerase (NS5B) inhibitors are described. A summary of the discovery of GSK5852 (3), a molecule which entered clinical trials in subjects infected with HCV in 2011, is included.

Original language	English
Journal	Journal of Medicinal Chemistry
Early online date	14 May 2013
DOIs	https://doi.org/10.1021/jm400317w
Publication status	Early online date - 14 May 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/jm400317w

Cite this

Maynard, A., Crosby, R. M., Ellis, B., Hamatake, R., Hong, Z., Johns, B. A., Kahler, K. M., Koble, C., Leivers, A. L., Leivers, M. R., Mathis, A., Peat, A. J., Pouliot, J. J., Roberts, C. D., Samano, V., Schmidt, R. M., Smith, G. K., Spaltenstein, A., Stewart, E. L., ... Shotwell, J. B. (2013). Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase. Journal of Medicinal Chemistry. Advance online publication. https://doi.org/10.1021/jm400317w

@article{5010f86c77f845a9a3dbb39e5849263e,

title = "Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase",

abstract = "A boronic acid moiety was found to be a critical pharmacophore for enhanced in vitro potency against wild type hepatitis C replicons and known clinical polymorphic and resistant HCV mutant replicons. The synthesis, optimization, and structure-activity relationships associated with inhibition of HCV replication in a sub-genomic replication system for a series of non-nucleoside boron-containing HCV RNA-Dependent RNA Polymerase (NS5B) inhibitors are described. A summary of the discovery of GSK5852 (3), a molecule which entered clinical trials in subjects infected with HCV in 2011, is included.",

author = "Andrew Maynard and Crosby, {Renae M} and Byron Ellis and Robert Hamatake and Zhi Hong and Johns, {Brian A} and Kahler, {Kirsten M} and Cecilia Koble and Leivers, {Anna L} and Leivers, {Martin R} and Amanda Mathis and Peat, {Andrew J} and Pouliot, {Jeffrey J} and Roberts, {Christopher D} and Vicente Samano and Schmidt, {Rachel M} and Smith, {Gary K} and Andrew Spaltenstein and Stewart, {Eugene L} and Pia Thommes and Turner, {Elizabeth M} and Christian Voitenleitner and Walker, {Jill T} and Greg Waitt and Jason Weatherhead and Weaver, {Kurt L} and Shawn Williams and Lois Wright and Xiong, {Zhiping Z} and David Haigh and Shotwell, {J Brad}",

year = "2013",

month = may,

day = "14",

doi = "10.1021/jm400317w",

language = "English",

journal = "Journal of Medicinal Chemistry",

publisher = "American Chemical Society",

}

Maynard, A, Crosby, RM, Ellis, B, Hamatake, R, Hong, Z, Johns, BA, Kahler, KM, Koble, C, Leivers, AL, Leivers, MR, Mathis, A, Peat, AJ, Pouliot, JJ, Roberts, CD, Samano, V, Schmidt, RM, Smith, GK, Spaltenstein, A, Stewart, EL, Thommes, P, Turner, EM, Voitenleitner, C, Walker, JT, Waitt, G, Weatherhead, J, Weaver, KL, Williams, S, Wright, L, Xiong, ZZ, Haigh, D & Shotwell, JB 2013, 'Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase', Journal of Medicinal Chemistry. https://doi.org/10.1021/jm400317w

TY - JOUR

T1 - Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase

AU - Maynard, Andrew

AU - Crosby, Renae M

AU - Ellis, Byron

AU - Hamatake, Robert

AU - Hong, Zhi

AU - Johns, Brian A

AU - Kahler, Kirsten M

AU - Koble, Cecilia

AU - Leivers, Anna L

AU - Leivers, Martin R

AU - Mathis, Amanda

AU - Peat, Andrew J

AU - Pouliot, Jeffrey J

AU - Roberts, Christopher D

AU - Samano, Vicente

AU - Schmidt, Rachel M

AU - Smith, Gary K

AU - Spaltenstein, Andrew

AU - Stewart, Eugene L

AU - Thommes, Pia

AU - Turner, Elizabeth M

AU - Voitenleitner, Christian

AU - Walker, Jill T

AU - Waitt, Greg

AU - Weatherhead, Jason

AU - Weaver, Kurt L

AU - Williams, Shawn

AU - Wright, Lois

AU - Xiong, Zhiping Z

AU - Haigh, David

AU - Shotwell, J Brad

PY - 2013/5/14

Y1 - 2013/5/14

N2 - A boronic acid moiety was found to be a critical pharmacophore for enhanced in vitro potency against wild type hepatitis C replicons and known clinical polymorphic and resistant HCV mutant replicons. The synthesis, optimization, and structure-activity relationships associated with inhibition of HCV replication in a sub-genomic replication system for a series of non-nucleoside boron-containing HCV RNA-Dependent RNA Polymerase (NS5B) inhibitors are described. A summary of the discovery of GSK5852 (3), a molecule which entered clinical trials in subjects infected with HCV in 2011, is included.

AB - A boronic acid moiety was found to be a critical pharmacophore for enhanced in vitro potency against wild type hepatitis C replicons and known clinical polymorphic and resistant HCV mutant replicons. The synthesis, optimization, and structure-activity relationships associated with inhibition of HCV replication in a sub-genomic replication system for a series of non-nucleoside boron-containing HCV RNA-Dependent RNA Polymerase (NS5B) inhibitors are described. A summary of the discovery of GSK5852 (3), a molecule which entered clinical trials in subjects infected with HCV in 2011, is included.

U2 - 10.1021/jm400317w

DO - 10.1021/jm400317w

M3 - Article

C2 - 23672667

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

ER -

Discovery of a Potent Boronic Acid Derived Inhibitor of the HCV RNA-Dependent RNA Polymerase

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this